только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 4 / 10
Страница 1 / 1

Список литературы

  1. Scully R.E., Young R.H., Clement P.B. Tumor like lesions. Tumors of the ovary and maldeveloped gonads, fallopian tube and broad ligament. Washington: Armed Forces Institute of Pathology, 1998. Pp. 443–444.
  2. Shih I.M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164(5):1511–8.
  3. Shih I.M., Kurman R.J. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005;11(20):7273–9.
  4. Kempson R.L., Hendrickson M.R. Ovarian serous borderline tumors: the citadel defended. Hum Pathol 2000;31(5):525–6.
  5. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 2005;123(Suppl.):13–57.
  6. International Statistical Classification of Diseases and Related Health Problems. 10th Revision.
  7. WHO Classification of tumors. Female genital tumours 5th edition, 2020Ayhan A., Akarin R., Develioglu O. et al. Borderline epithelial ovarian tumors. Aust N Z J Obstet Gynecol 1991;31(2):174–6.
  8. Губина О.В. Особенности клинического течения и лечения пограничных опухолей яичников. Автореф. дис. … канд. мед. наук. М., 1995.
  9. Ledermann J. A., Raja F. A., Fotopoulou C. et al. Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines // Ann Oncol. – 2013. –V. 24 (Suppl 6). – P. vi24–vi32.
  10. Давыдова И.Ю., Карселадзе А.И., Кузнецов В.В. и др. Практические рекомендации по лекарственному лечению пограничных опухолей яичников. Злокачественные опухоли: практические рекомендации RUSSCO, 2018 г. Т. 8. С. 171–177.
  11. Ebell M.H., Culp M.B., Radke T.J. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med 2016;50(3):384–94.
  12. NCCN guidelines panel. Epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). Version 1.2016. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian.
  13. Stiekema A., Boldingh Q.J., Korse C.M. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecol Oncol 2015;136(3):562–6.
  14. Santotoribio J.D., Garcia de la Torre A., Cañavate-Solano C. et al. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors. Eur J Gynaecol Oncol 2016;37(1):26–9.
  15. Morotti M. et al. The preoperative diagnosis of borderline ovarian tumors: a review of current literature //Archives of gynecology and obstetrics. – 2012. – Т. 285. – С. 1103-1112.
  16. Lenhard M. et al. Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer //BMC cancer. – 2012. – Т. 12. – С. 1-8.
  17. Ledermann J.A., Raja F.A., Fotopoulou C. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol 2013;24(Suppl 6):vi24–32.
  18. Levi F. et al. Second neoplasms after invasive and borderline ovarian cancer //European Journal of Cancer Prevention. – 2009. – Т. 18. – №. 3. – С. 216-219.
  19. Trimbos J.B., Parmar M., Vergote I. et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95(2):105–12.
  20. Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 2013;22(17):S23–30.
  21. NCCN Guidelines Version 1.2019 Ovarian Borderline Epithelial Tumors. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian.
  22. Vasconcelos I. Management of borderline ovarian tumors state of the art. Uterus & Ovary 2015;2:1–6. DOI: 10.14800/uo.885.
  23. Vasconcelos I. Conservative surgery in ovarian borderline tumours: A meta-analysis with emphasis on recurrence risk. Eur J Cancer 2015;51(5):620–31.
  24.  
  25. Camatte S., Morice P., Thoury A. et al. Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 2004;40(12):1842–9.
  26. Новикова Е.Г., Баталова Г.Ю. Пограничные опухоли яичников. М.: Медицинское информационное агентство, 2007. 152 с.
  27. Trillsch F. Mahner S., Ruetzel J.D. et al. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther 2010;10(7):1115–24.
  28. Новикова Е.Г., Шевчук А.С., Завалишина Л.Э. Некоторые аспекты органосохраняющего лечения пограничных опухолей яичников. Российский онкологический журнал 2010;(4):15–20.
  29. Ushijima K., Kawano K., Tsuda N. et al. Epithelial borderline ovarian tumor: Diagnosis and treatment strategy. Obstet Gynecol Sci 2015;58(3):183–7.
  30. Kleppe М., Bruls J., van Gorp T. et al. Mucinous borderline tumours of the ovary and the appendix: a retrospective study and overview of the literature Gynecol. Oncol 2014;133(2):155–8.
  31. Morice P., Camatte S., Wicart-Poque F. et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod 2003;9(2):185–92.
  32. Карселадзе А.И. К морфологии муцинозных пограничных опухолей яичников. Архив патологии 1989;51(5):40–6.
  33. Du Bois A., Ewald-Riegler N., du Bois O., Harter P. Borderline tumors of the ovary: a systematic review. Geburtsh Frauenheilk 2009;69:807–33.
  34. Абузарова Г.Р., Арутюнов Г.П. Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи. Клинические рекомендации, 2018 г.
  35. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment- related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92(8):715–27.
  36. Nilsson H., Angeras U., Bock D., Börjesson M., Onerup A., Fagevik Olsen M., Gellerstedt M., Haglind E., Angenete E. Is preoperative physical activity related to post-surgery recovery? BMJ Open. 2016 Jan 14;6(1):e007997. doi: 10.1136/bmjopen-2015-007997.
  37. Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol. 2015 Dec;22(13):4117-23. doi: 10.1245/s10434-015-4550-z. Epub 2015 Apr 14.
  38. Nelson G., Bakkum-Gamez J., Kalogera E. et al Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations – 2019 update International Journal of Gynecologic Cancer Published Online First: 15 March 2019. doi: 10.1136/ijgc-2019-000356.
  39. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward // Journal of the American College of Surgeons. – 2010. –Vol. 210, No. 4 – pp. 491–495.
  40. Goerling U., Jaeger C., Walz A. et al. The efficacy of psycho-oncological interventions for women with gynaecological cancer: A randomized study // Oncology. 2014;87:114–124. Crossref, Medline.
  41. Shehadeh A., El Dahleh M., Salem A. et al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients’ outcome. Hematol Oncol Stem Cell Ther 2013;6(3–4):105–11.
  42. Marchese V.G., Spearing E., Callaway L. et al. Relationships among range of motion, functional mobility, and quality of life in children and adolescents after limb-sparing surgery for lower-extremity sarcoma. Pediatr Phys Ther 2006;18(4):238–44.
  43. Cox C.L., Montgomery M., Oeffinger K.C. et al. Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009;115(3):642–54.
  44. Tinelli F., Tinelli R., La Grotta F. et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet Gynecol Scand 2007;86(1):81–7.
  45. Mooney J., Silva E., Tornos C. et al. Unusual features of serous neoplasms of low malignant potential during pregnancy. Gynecol Oncol 1997;65(1):30–5.
  46. Kaern J., Tropé C.G., Abeler V.M. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993;71(5):1810–20.
  47. Morice P., Camatte S., Wicart-Poque F. et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update 2003;9(2):185–92.
  48. Fischerova D. et al. Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study //Ultrasound in Obstetrics & Gynecology. – 2017. – Т. 49. – №. 2. – С. 263-274.
  49. Oken M.M., Creech R.H., Tormey D.C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982,5(6):649–55.
  50. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191-205
  51. Т.А. Назаренко, А.Г. Бурдули, Я.О. Мартиросян, Л.Г. Джанашвили Криоконсервация репродуктивного материала у онкологических больных. Акушерство и Гинекология N9/2019, С.40-48
  52. C. Rousset-Jablonski et al. Gynecol. Obstet.. Fertil. Senol. 2020 Mar.
  53. Sahin F. et al. Borderline ovarian tumors: twenty years of experience at a tertiary center //Anatolian Current Medical Journal. – 2023. – Т. 5. – №. 3. – С. 196-200.
  54. Diniz G. et al. Expression of human epididymal secretory protein 4 may be a predictor for invasiveness in ovarian epithelial tumors //Eur. J. Gynaecol. Oncol. – Т. 38. – №. 6. – С. 2017.
  55. Minar L. et al. Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors //International Journal of Gynecology & Obstetrics. – 2018. – Т. 140. – №. 2. – С. 241-246.
  56. Robertson D. M. et al. Inhibins and ovarian cancer //Molecular and cellular endocrinology. – 2004. – Т. 225. – №. 1-2. – С. 65-71.
  57. Matsas A. et al. Tumor markers and their diagnostic significance in ovarian cancer //Life. – 2023. – Т. 13. – №. 8. – С. 1689.
  58. Carbonnel M. et al. Serous borderline ovarian tumor diagnosis, management and fertility preservation in young women //Journal of Clinical Medicine. – 2021. – Т. 10. – №. 18. – С. 4233.
  59. Park J. Y. et al. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery //Gynecologic oncology. – 2009. – Т. 113. – №. 1. – С. 75-82.
  60. Chen R. et al. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience //Journal of Ovarian Research. – 2016. – Т. 9. – С. 1-8.
  61. Tal O. et al. Characteristics and prognosis of borderline ovarian tumors in pre and postmenopausal patients //Archives of Gynecology and Obstetrics. – 2020. – Т. 302. – С. 693-698.
  62. Raimondo D. et al. The impact of hysterectomy on oncological outcomes in postmenopausal patients with borderline ovarian tumors: A multicenter retrospective study //Frontiers in Oncology. – 2022. – Т. 12. – С. 1009341